Securities code: 002332 securities abbreviation: Zhejiang Xianju Pharmaceutical Co.Ltd(002332) Announcement No.: 2022-007
Zhejiang Xianju Pharmaceutical Co.Ltd(002332)
2021 annual performance express
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without falsehood
False records, misleading statements or material omissions.
Special note: the financial data of 2021 contained in this announcement is only preliminary accounting data and has been used in the company
The Audit Department of the Ministry of audit, without the audit of an accounting firm, may be inconsistent with the final data disclosed in the annual report
In terms of differences, investors should pay attention to investment risks.
1、 Main financial data and indicators in 2021
Unit: (RMB)
Increase / decrease range of the project in the same period of last year in the reporting period (%)
Total operating income 4345284809.20 4018872772.40 8.12
Operating profit 740550688.87 597237644.44 24.00
Total profit 731682212.68 621248494.85 17.78
Net profit attributable to shareholders of listed company 609770740.85 504509427.41 20.86
Net profit attributable to shareholders of listed company after deducting non recurring profit and loss 571014101.63 459591327.12 24.24
Basic earnings per share 0.62 0.55 12.73
Weighted average return on net assets 13.20%, 15.46% – 2.26%
Increase / decrease range at the end of the reporting period (%)
Total assets 6732401902.86 6838231066.49 -1.55
Owner’s equity attributable to shareholders of listed companies 4821818144.62 4444931882.40 8.48
Share capital 989204866.00 989204866.00 0
Net assets per share attributable to shareholders of listed companies 4.87 4.49 8.46
Note: the above data are filled in with the unaudited consolidated statements of the company.
2、 Description of operating performance and financial status
1. Operating performance: during the reporting period, the company achieved an operating revenue of 4345.2848 million yuan, a year-on-year increase of 8.12%; The operating profit was 74.5507 million yuan, a year-on-year increase of 24%; The total profit was 731682200 yuan, a year-on-year increase of 17.78%; The net profit attributable to the shareholders of the listed company was 609770700 yuan, a year-on-year increase of 20.86%; Earnings per share was 0.62 yuan, a year-on-year increase of 12.73%.
During the reporting period, the company’s operating revenue, total profit and net profit attributable to shareholders of listed companies maintained year-on-year growth, mainly due to the growth of the company’s preparation business in 2021, especially the rapid growth of respiratory products. The API business overcame the impact of the relocation and optimization of Yangfu new plant area and remained stable as a whole. The company focuses on the main business of steroids, focuses on technical improvement, and speeds up the development of preparation products and the construction of API technology platform. 2. Financial status: at the end of the reporting period, the total assets of the company were 6732.4019 million yuan, a year-on-year decrease of 1.55%; The owner’s equity attributable to the shareholders of listed companies was 4821818100 yuan, a year-on-year increase of 8.48%.
3、 Description of the difference from the previous performance forecast
Before the disclosure of this performance express, according to the relevant regulations of the exchange, the company did not make an expected disclosure of the operating performance in 2021.
4、 Documents for future reference
1. Comparative balance sheet and income statement signed and sealed by the legal representative of the company, the person in charge of accounting work and the person in charge of accounting organization.
2. The internal audit report signed by the head of the internal audit department.
It is hereby announced.
Zhejiang Xianju Pharmaceutical Co.Ltd(002332)
Board of directors
February 25, 2022
